[The problem of insomnia in infant/young children: issues of diagnosis and treatment]. / Problemy narusheniya sna u detei rannego vozrasta: voprosy diagnostiki i korrektsii.

OBJECTIVE: To obtain further evidence of the efficacy of dormikind in infant/young children. MATERIAL AND METHODS: The study was performed in the group of 114 patients, aged 6 months to 2.5 years, with sleep and sleep initiation disorders. Sixty-four patients received treatment with dormikind (group 1) and 50 patients received behavioral therapy (group 2) for 28 days. RESULTS AND CONCLUSION: In group 1, sleep initiation decreased by 1.7 times and reached 26.2±4.8 minutes, the number of children sleeping on hands dropped by 8.7 times and sleeping in the parent's bed by 2 times. In group 2, the same characteristics changed by 1.1, 1.3 and 1.5 times, respectively, and sleep initiation reached 33.4±2.9 minutes. The number of patients of group 1 falling asleep in their own beds increased by 3.2 times vs 1.2 times in group 2. Duration of night sleep increased and frequency of awakening reduced as well. The significant positive dynamics was noted in the emotional-behavior state of children after therapy: the total score significantly improved by 2.9 times to the end of treatment compared to group 2 (by 1.3 times). IMOS score showed significant difference between the groups on «total recovery¼ and «significant improvement¼. Therefore, the high efficacy and safety of dormikind in children have been confirmed.

[Clinical polymorphism of malignant epilepsy of infancy with migrating multifocal seizures (8 cases)].

Malignant migrating partial seizures in infancy are rare epilepsy syndrome that begins in the first 6 months of life and characterized by multiple continuous electroencephalographic and electroclinical focal ictal patterns which involved different independent areas of both hemispheres with arrest of psychomotor development. The present detailed review is based on the personal observation of 8 patients newly diagnosed at the Russian Children Clinical hospital, Moscow, Russia. At least three ictal patterns recorded from different independent areas of both hemispheres were fixed by video-EEG-monitoring in all patients. The high polymorphism and very frequent seizures (not less than five types at every child) were observed. The cases were pharmacoresistant, with the absence of reaction to antiepileptic therapy and progressive deterioration in 4 (50%) patients. Decreasing of seizure frequency by 50% was achieved in 3 (37.5%) patients treated with the combination of valproates, benzodiazepines and barbiturates and by 75% in 1 (12.5%) patient case treated with valproates, benzodiazepines and levetyracetam (keppra). The authors proposed a definition of this epileptic syndrome as: "malignant epilepsy of infancy with migrating multifocal seizures".

[Use of reminyl (galantamine) in the treatment of dementia].

Clinical efficacy and safety of reminyl monotherapy has been studied in patients with dementia of Alzheimer's and mixed vascular-degenerative types. The reminyl treatment has been conducted in dosage of 16 mg/kg daily during 6 months in 30 patients (20 female, 10 male) aged from 59 to 86 years. The results of the study revealed high efficacy of reminyl in the treatment of patients with mild and moderate dementia and good tolerability of the medication.